论文部分内容阅读
目的 探讨接受拉米夫定治疗的慢性乙型肝炎病毒 (HBV)感染者YMDD基序变异的分子生物学机理。方法 以RFLP法筛选HBVYMDD基序变异 ,阳性者作直接测序的方法 ,分别检测 1 9例正在应用拉米夫定治疗的慢性乙型肝炎患者以及 86例未用拉米夫定的HBV感染者的血清标本。结果 1 9例正在应用拉米夫定治疗的患者中检测出 2例YMDD基序变异 ,测序结果分别为YIDD和YVDD变异。在 86例未用拉米夫定或其他抗病毒药物治疗的HBV感染者中检测出 3例YMDD基序变异 ,测序结果分别为YIDD 1例和YVDD 2例。结论 在未用拉米夫定的HBV感染者中同样存在着YMDD基序变异 ,提示使用拉米夫定后出现的YMDD基序变异的可能原因之一是有效抗病毒药物对HBV病毒群筛选的结果
Objective To investigate the molecular mechanism of YMDD motif mutation in patients with chronic hepatitis B virus (HBV) infection after lamivudine treatment. Methods RFLP method was used to screen HBV YMDD motif mutation. The positive individuals were sequenced directly. The detection of 19 hepatitis B patients who were treated with lamivudine and 86 HBV infected patients who did not use lamivudine Serum samples. Results Two cases of YMDD motif mutation were detected in 19 cases of patients who were treated with lamivudine. The sequencing results were YIDD and YVDD. Three cases of YMDD motif mutation were detected in 86 HBV infected patients who were not treated with lamivudine or other antiviral drugs. The sequencing results were 1 case of YIDD and 2 cases of YVDD. Conclusions There is also a YMDD motif mutation in HBV-infected patients without lamivudine, which indicates that one of the possible causes of YMDD motif mutation after lamivudine screening is that antiviral drugs screen the HBV population result